An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.

① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.

cls.cnJan 9 08:38 ET

China Accepts Shanghai Junshi Biosciences' Clinical Trial for Antitumor Injection

MT NewswiresJan 9 03:59 ET

Express News | Shanghai Junshi Biosciences - Js212 Injection Received Acceptance Notice for Investigational New Drug Application Bby China Nmpa

ReutersJan 8 05:40 ET

JUNSHI BIO (688180.SH): The injection JS212 has received the acceptance notification for its clinical trial application.

On January 8, 2023, Gelonghui reported that JUNSHI BIO (688180.SH) announced the receipt of the "Acceptance Notification" issued by the National Medical Products Administration, and the clinical trial application for the injectable JS212 (project code "JS212") has been accepted. JS212 is a recombinant humanized bispecific antibody-drug conjugate targeting the epidermal growth factor receptor (referred to as "EGFR") and the human epidermal growth factor receptor 3 (referred to as "HER3"), primarily used for the treatment of advanced malignant solid tumors. EGFR and HER3 are highly expressed on the surface of various tumor cells, such as

Gelonghui FinanceJan 8 03:34 ET

Shanghai Junshi Biosciences Gets Regular Approval for Skin Cancer Drug

MT NewswiresJan 6 23:30 ET

Express News | Shanghai Junshi Biosciences - Regular Approval of Toripalimab as Second-Line or Later Treatment of Melanoma by Nmpa

ReutersJan 6 08:19 ET